Similarly, a liver-mediated gene therapy to treat MPSVI, a different MPS disease that also affects the skeletal system, with a very similar gene transfer strategy (AAV8-TGB-Arsb) did not mediate complete correction of the bone pathology in the animal models evaluated26,69. The gene discussed is ARSB; the disease is mucopolysaccharidosis type 6.